Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT03333746 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Study was discontinued due to FDA recommendations of the potential toxicities of the combination of drugs.

Conditions

Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Lenalidomide
BIOLOGICAL: Nivolumab
OTHER: Pharmacological Study

Sponsor

Yvonne Efebera

Collaborators

[object Object]
[object Object]
[object Object]